FDA grants Breakthrough Device Designation to neuromodulation technology for post‑aneurysm vessel narrowing

A non‑invasive neuromodulation system has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration. The designation applies to the technology’s intended use in mitigating cerebral vasospasm—a severe narrowing of brain blood vessels that can develop after a hemorrhagic stroke caused by a ruptured aneurysm.

The FDA’s designation is intended to accelerate the development and review of devices that address unmet medical needs. By facilitating more frequent communication with the agency and allowing for priority review, the designation could shorten the timeline for clinical trials and eventual market entry. If successful, the neuromodulation approach would offer a non‑surgical option to reduce the risk of delayed ischemic injury, a leading cause of morbidity and mortality in patients recovering from aneurysmal subarachnoid hemorrhage. The sponsor plans to initiate pivotal studies later this year, aiming to demonstrate safety and efficacy before seeking full regulatory clearance.